Predicting the in vivo biological behaviour of
new chemical entities using customized in vitro pharmacology and ADME-Tox assays.
Our customized assay development services include a full range of assays and technologies adapted to clients specific needs. Whether
performing a million-compound primary screening, or secondary profiling, you need tools that accurately predict human biology. Cerep
has an impressive and integrated suite of core competencies that will be valuable to your drug discovery programs.
A key driver of success in the drug discovery process is predicting the in vivo biological behaviour of new chemical entities using
customized in vitro pharmacology and ADME-Tox assays.
Custom assays can be developed based on either Cerep or clientsí own technology, using clients biological material, Cerepís
in-house produced, or commercially available biological material.
Cerepís assay development service draws on the knowledge and the experience of 300 professionals. Our expertise includes customized
binding, cellular and tissue assays on absorption, distribution, metabolism and toxicity related targets; peptide and non-peptide
GPCRs; various enzymes, transporters, nuclear receptors and ion channels. Through our extended know-how we propose a wide range of
human and animal models (for a complete list, please contact us).
Methods and process
Each assay development is a new project
Following clients request, a feasibility study (in 48 hours) allows us to understand the perimeter of
specifications and to propose the most suitable solution in a customized quotation (1 week).
Upon clients approval a detailed development process and validation criteria are established jointly.
Cerep offers development of new targets by first performing molecular cloning, transient and/or stable transfection followed by
development of the assay. Each part of the development project involves a dedicated group of specialists. Each development is managed
as a project with a study director establishing and validating each step (go no-go steps defined with the client). If requested,
clientís reference compounds can be used for the final validation of the assay. Dedicated support services will take care of
transfer of raw material and reference compounds when necessary.
Depending on client needs, the assay can be transferred or industrialized by Cerep and adapted to high throughput screening
Development reports will be prepared and archived for 10 years.
Cerepís customized assay development group is partner to:
Update selectivity and safety target panel
Screen chemical libraries on recently deorphanized targets
Create an evolving assay panel according to the evolution of a drug discovery program
Address reorientation of research programs rapidly
Accelerate the lead optimization process
Consolidate assay development and screening while maintaining quality levels
Implement proprietary assays
Free up in-house capacity to pursue additional leads for drug development.